Pre-Eclampsia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pre-Eclampsia – Pipeline Review, H2 2016’, provides an overview of the Pre-Eclampsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia

The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects

The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

Alnylam Pharmaceuticals, Inc.

Glenveigh Medical, LLC

LFB S.A.

Pluristem Therapeutics Inc.

VG Life Sciences, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pre-Eclampsia Overview 6

Therapeutics Development 7

Pipeline Products for Pre-Eclampsia - Overview 7

Pipeline Products for Pre-Eclampsia - Comparative Analysis 8

Pre-Eclampsia - Therapeutics under Development by Companies 9

Pre-Eclampsia - Therapeutics under Investigation by Universities/Institutes 10

Pre-Eclampsia - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Pre-Eclampsia - Products under Development by Companies 13

Pre-Eclampsia - Products under Investigation by Universities/Institutes 14

Pre-Eclampsia - Companies Involved in Therapeutics Development 15

A1M Pharma AB 15

Alnylam Pharmaceuticals, Inc. 16

Glenveigh Medical, LLC 17

LFB S.A. 18

Pluristem Therapeutics Inc. 19

VG Life Sciences, Inc. 20

Pre-Eclampsia - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

A1M-001 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

ALN-AGT - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

antithrombin (recombinant) - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

digoxin immune fab - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PLX-PAD - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

RMC-035 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

VG-1177 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Pre-Eclampsia - Dormant Projects 51

Pre-Eclampsia - Product Development Milestones 52

Featured News & Press Releases 52

Mar 22, 2016: A1M Pharma finalizes drug candidate for treating pre-eclampsia and files for substance patent 52

Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Pre-eclampsia 52

Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Pre-eclampsia and Indicates Their Superiority Over Other Cells 53

Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem’s PLX-PAD Cells for Treatment of Severe Pre-eclampsia 54

Sep 24, 2015: New clinical trial at SLU treats pre-eclampsia in second-trimester pregnancies 54

Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Pre-eclampsia 55

Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 57

Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Pre-eclampsia (PRESERVE-1) 57

Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma’s Treatment for Pre-eclampsia 58

Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Pre-eclampsia 58

Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Pre-eclampsia 59

Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Pre-eclampsia 60

Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model 60

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development for Pre-Eclampsia, H2 2016 7

Number of Products under Development for Pre-Eclampsia – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Pre-Eclampsia – Pipeline by A1M Pharma AB, H2 2016 15

Pre-Eclampsia – Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 16

Pre-Eclampsia – Pipeline by Glenveigh Medical, LLC, H2 2016 17

Pre-Eclampsia – Pipeline by LFB S.A., H2 2016 18

Pre-Eclampsia – Pipeline by Pluristem Therapeutics Inc., H2 2016 19

Pre-Eclampsia – Pipeline by VG Life Sciences, Inc., H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Pre-Eclampsia – Dormant Projects, H2 2016 51

List of Figures

List of Figures

Number of Products under Development for Pre-Eclampsia, H2 2016 7

Number of Products under Development for Pre-Eclampsia – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 22

Number of Products by Stage and, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports